Adherence to Antiretroviral Therapy During and After Pregnancy: Cohort Study on Women Receiving Care in Malawi's Option B+ Program

Andreas D. Haas(Institute of Social and Preventive Medicine), Olivia Keiser(University of Bern), Joep J. van Oosterhout(Dignitas International), Andreas Jahn(University of Washington), Frank Chimbwandira(Centers for Disease Control and Prevention), Adrian Spoerri(Institute of Social and Preventive Medicine), Janne Estill(University of Geneva), Oliver Jintha Gadabu(Research for Equity And Community Health Trust), Nozgechi Phiri(Institute of Social and Preventive Medicine), Kali Tal(Institute of Social and Preventive Medicine), Matthias Egger(University of Bern), Malango Msukwa(University of Bern), Hannock Tweya(International Union Against Tuberculosis and Lung Disease), Luisa Salazar‐Vizcaya(University of Bern), Lyson Tenthani(Ministry of Health)
Clinical Infectious Diseases
July 26, 2016
10.1093/cid/ciw500
Cited by 166

Related Papers

Cancer Risk in the Swiss HIV Cohort Study: Associations With Immunodeficiency, Smoking, and Highly Active Antiretroviral Therapy
|JNCI Journal of the National Cancer Institute|2005|857
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial
|The Lancet Oncology|2016|738
Predatory journals: no definition, no defence
|Nature|2019|716
Retention in care under universal antiretroviral therapy for HIV-infected pregnant and breastfeeding women (‘Option B+’) in Malawi
|AIDS|2014|375
Changing patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV Cohort Study
|British Journal of Cancer|2010|301